NCT00463749

Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein

Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 251 (actual)
• Sponsor: University of Leipzig · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration. In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy. Furthermore, it might reduce infarct size as a result of its antioxidant properties. Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Acetylcystein	high-dose N-Acetylcystein during PCI and for 2/day for 2 days
DRUG	Placebo	NaCl as placebo

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-02-01
• Completion: 2008-06-01
• First posted: 2007-04-20
• Last updated: 2008-07-08

Locations

1 site across 1 country: Germany